Latest revenue
$15.0K
as of 2026-03-31
Latest net income
$-78.7M
as of 2026-03-31
Net margin
-524566.7%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.41B
- Enterprise value
- $2.41B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $35.79
- 52-wk low
- $18.55
- Beta
- —
- Shares out
- 78.5M
5-year trend
What this company does
Item 1. BUSINESS Overview Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Our drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. We are focusing our efforts and resources on the continued research and…
AI summary unavailable — showing raw filing excerpt
Generated from CLDX's filing dated 2026-02-25
Key risks
Item 1A. RISK FACTORS You should consider carefully these risk factors together with all of the information included or incorporated by reference in this Annual Report in addition to our financial statements and the notes to our financial statements. This section includes forward-looking statements. The following is a discussion of the risk factors that we believe are material to us at this time. These risks and uncertainties are not the only ones facing us, and there may be additional matters that we are unaware of or that we currently consider immaterial. All of these could adversely affect our business, results of operations, financial condition and cash flows. Summary of Risk Factors…
AI summary unavailable — showing raw filing excerpt
Generated from CLDX's filing dated 2026-02-25
Profitability
Operating margin
-18599.8%
569.3%Net margin
-16748.0%
644.8%Return on equity
-49.1%
132.3%Return on assets
-44.4%
122.8%Leverage
Debt / equity
0.11×
74.5%Debt / assets
9.6%
67.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $15.0K | -97.8% | $-78.7M | -46.3% | -524566.7% |
Q4 2025 2025-12-31 | $-1.3M | -211.0% | $-81.3M | — | — |
Q3 2025 2025-09-30 | $1.4M | -55.4% | $-67.0M | -59.2% | -4708.1% |
Q2 2025 2025-06-30 | $730.0K | -70.8% | $-56.6M | -57.9% | -7753.4% |
Q1 2025 2025-03-31 | $695.0K | +345.5% | $-53.8M | — | -7740.4% |
Q4 2024 2024-12-31 | $1.2M | — | — | — | — |
Q3 2024 2024-09-30 | $3.2M | +110.3% | $-42.1M | — | -1320.0% |
Q2 2024 2024-06-30 | $2.5M | +832.1% | $-35.8M | — | -1434.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
In Vitro & In Vivo Diagnostic Substances · SIC 2835
Your notes
Keep private notes on CLDX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$1.3M
Net activity
−$1.3M
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CLDX
Institutional value
$533.8M
Total shares held
17.0M
Distinct holders
113
-73 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.4M | $170.3M | -81.9K (-1.5%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | $93.9M | — | New |
| 3 | DIMENSIONAL FUND ADVISORS LP | 1.1M | $33.6M | +407.8K (+62.6%) | Added |
| 4 | Fisher Asset Management, LLC | 1.0M | $32.2M | +76.5K (+8.2%) | Added |
| 5 | Pictet Asset Management Holding SA | 923.7K | $29.3M | -44.9K (-4.6%) | Trimmed |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 629.3K | $20.0M | — | New |
| 7 | VANGUARD FIDUCIARY TRUST CO | 429.6K | $13.6M | — | New |
| 8 | TSP Capital Management Group, LLC | 375.1K | $11.9M | +0 (+0.0%) | No change |
| 9 | KENNEDY CAPITAL MANAGEMENT LLC | 352.3K | $11.2M | — | New |
| 10 | UBS Group AG | 297.0K | $9.4M | -29.5K (-9.0%) | Trimmed |
| 11 | Candriam S.C.A. | 278.9K | $8.8M | — | New |
| 12 | CITIGROUP INC | 217.3K | $6.9M | +202.4K (+1356.5%) | Added |
| 13 | Nuveen, LLC | 201.9K | $6.4M | +1.3K (+0.6%) | Added |
| 14 | Bank of New York Mellon Corp | 190.4K | $6.0M | -4.2K (-2.1%) | Trimmed |
| 15 | Connor, Clark & Lunn Investment Management Ltd. | 184.1K | $5.8M | +65.9K (+55.7%) | Added |
| 16 | Mirador Capital Partners LP | 178.1K | $5.6M | +7.4K (+4.3%) | Added |
| 17 | BNP PARIBAS FINANCIAL MARKETS | 175.8K | $5.6M | -54.9K (-23.8%) | Trimmed |
| 18 | JPMORGAN CHASE & CO | 164.8K | $4.9M | -8.9K (-5.1%) | Trimmed |
| 19 | Assenagon Asset Management S.A. | 146.5K | $4.6M | — | New |
| 20 | DEUTSCHE BANK AG\ | 143.0K | $4.5M | +6.6K (+4.8%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CLDX's latest filing finishes processing.